Neuroprotection by memantine against neurodegeneration induced by β-amyloid(1-40)

Brain Research

Volumn 958, Issue 1, 2002, Pages 210-221

  Miguel Hidalgo, J J ^a   Alvarez, X A ^b   Cacabelos, R ^b   Quack, G ^c  

^a UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^b Centro de Investigacion Biomedica EuroEspes   (Spain)

^c MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

Alzheimer's disease; Amyloid; Behavior; Hippocampus; Neurotoxicity; NMDA receptor

Indexed keywords

AMYLOID BETA PROTEIN; MEMANTINE; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASTROCYTE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MECHANISM; FEMALE; HIPPOCAMPUS; HYPERTROPHY; IMMUNOHISTOCHEMISTRY; LEARNING DISORDER; MICROGLIA; NERVE CELL DEGENERATION; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; RAT; RAT STRAIN; SPATIAL DISCRIMINATION; STEADY STATE; STRUCTURE ANALYSIS; TIME;

EID: 0037146905     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(02)03731-9     Document Type: Article

References (58)

1. Alvarez X.A., Franco A., Fernandez-Novoa L., Cacabelos R. Effects of betahistine on locomotor activity and passive avoidance behavior in rats. Agents Actions. 38:(Special Conference Issue):1993;1-3.
2. Alvarez X.A., Miguel-Hidalgo J.J., Fernandez-Novoa L., Cacabelos R. Intrahippocampal injections of the β-amyloid 1-28 fragment induces behavioral deficits in rats. Meth. Find Exp. Clin. Pharmacol. 19:1997;471-479.
3. Amenta F., Bronzetti E., Sabbatini M., Vega J.A. Astrocyte changes in aging cerebral cortex and hippocampus: a quantitative immunohistochemical study. Microsc. Res. Tech. 43:1998;29-33.
4. Beal M.F. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann. Neurol. 31:1992;119-130.
5. Block F., Schwarz M. Memantine reduces functional and morphological consequences induced by global ischemia in rats. Neurosci. Lett. 208:1996;41-44.
6. Chen G., Chen K.S., Knox J., Inglis J., Bernard A., Martin S.J., Justice A., McConlogue L., Games D., Freedman S.B., Morris R.G. A learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer's disease. Nature. 408:2000;975-979.
7. Chen H.S., Wang Y.F., Rayudu P.V., Edgecomb P., Neill J.C., Segal M.M., Lipton S.A., Jensen F.E. Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following postischemic administration and do not block maze learning or long-term potentiation. Neuroscience. 86:1998;1121-1132.
8. Cheng H.W., Jiang T., Brown S.A., Pasinetti G.M., Finch C.E., McNeill T.H. Response of striatal astrocytes to neuronal deafferentation: an immunocytochemical and ultrastructural study. Neuroscience. 62:1994;425-439.
9. Danysz W., Parsons C.G., Bresink I., Quack G. Glutamate in CNS disorders. Drugs News Pers. 8:1995;261-277.
10. Danysz W., Parsons C.G., Möbius H.-J., Stöffler A., Quack G. Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease - a unified glutamatergic hypothesis on the mechanism of action. Neurotox. Res. 2:2000;85-97.
11. Danysz W., Zajaczkowski W., Parsons C.G. Modulation of learning processes by ionotropic glutamate receptor ligands. Behav. Pharmacol. 6:1995;455-474.
12. Dawson D.A., Hallenbeck J.M. Acute focal ischemia-induced alterations in MAP2 immunostaining: description of temporal changes and utilization as a marker for volumetric assessment of acute brain injury. J. Cereb. Blood Flow Metab. 16:1996;170-174.
13. Dewachter I., van Dorpe J., Spittaels K., Tesseur I., Van Den Haute C., Moechars D., Van Leuven F. Modeling Alzheimer's disease in transgenic mice: effect of age and of presenilin1 on amyloid biochemistry and pathology in APP/London mice. Exp. Gerontol. 35:2000;831-841.
14. Dogan A., Eras M.A., Rao V.L., Dempsey R.J. Protective effects of memantine against ischemia-reperfusion injury in spontaneously hypertensive rats. Acta Neurochir. (Wien). 141:1999;1107-1113.
15. +: implications for neurodegeneration. J. Neurochem. 63:1994;584-591.
16. Ehrlich M., Knolle E., Ciovica R., Bock P., Turkof E., Grabenwoger M., CartesZumelzu F., Kocher A., Pockberger H., Fang W.C., Wolner E., Havel M. Memantine for prevention of spinal cord injury in a rabbit model. J. Thor. Cardiovasc. Surg. 117:1999;285-291.
17. Erdo S.L., Schafer M. Memantine is highly potent in protecting cortical cultures against excitotoxic cell death evoked by glutamate and N-methyl-D-aspartate. Eur. J. Pharmacol. 198:1991;215-217.
18. Forloni G., Chiesa R., Smiroldo S., Verga L., Salmona M., Tagliavini F., Angeretti N. Apoptosis mediated neurotoxicity induced by chronic application of β-amyloid fragment 25-35. NeuroReport. 4:1993;523-526.
19. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F., Guido T., Hagopian S., Johnson-Wood K., Khan K., Lee M., Leibowitz P., Lieberburg I., Little S., Masliah E., McConlogue L., Montoya-Zavala M., Mucke L., Paganini L., Penniman E., Power M., Schenk D., Seubert P., Snyder B., Soriano F., Tan H., Vitale J., Wadsworth S., Wolozin B., Zhao J. Alzheimer type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature. 373:1995;523-527.
20. Gray C.W., Patel A.J. Neurodegeneration mediated by glutamate and β-amyloid peptide: a comparison and possible interaction. Brain Res. 691:1995;169-179.
21. Greenamyre J.T., Maragos E.F., Albin R.L., Penney J.B., Young A.B. Glutamate transmission and toxicity in Alzheimer's disease. Prog. Neuro-Psych. Biol. Psych. 12:1988;421-430.
22. Harrigan M.R., Kunkel D.D., Nguyen L.B., Malouf A.T. Beta amyloid is neurotoxic in hippocampal slice cultures. Neurobiol. Aging. 16:1995;779-789.
23. Higgins L.S. Animal models of Alzheimer's disease. Mol. Med. Today. 5:1999;274-276.
24. Hoyer S. Oxidative metabolism deficiencies in brains of patients with Alzheimer's disease. Acta Neurol. Scand. 93:1996;18-24.
25. Hunter A.J., Green R., Cross A.J. Animal models of acute ischaemic stroke: can they predict clinically successful neuroprotective drugs? Trends Pharmacol. Sci. 16:1995;123-128.
26. Hyman B.T., Tanzi R.E., Marzloff B.A., Barbour R., Schenk D.B. Kunitz protease inhibitor-containing amyloid β-protein precursor immunoreactivity in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 51:1992;76-83.
27. Jain K.K. Evaluation of memantine for neuroprotection in dementia. Exp. Opin. Invest. Drugs. 9:2000;1397-1406.
28. Kanayama G., Takeda M., Morihara T., Miyamae Y., Shinozaki K., Nishikawa T., Niigawa H., Nishimura T. Temporal and regional profiles of cytoskeletal protein accumulation in the rat brain following traumatic brain injury. Psychiatry Clin. Neurosci. 51:1997;157-165.
29. Kanayama G., Takeda M., Niigawa H., Ikura Y., Tamii H., Taniguchi N., Kudo T., Miyamae Y., Morihara T., Nishimura T. The effects of repetitive mild brain injury on cytoskeletal protein and behavior. Meth. Find Exp. Clin. Pharmacol. 18:1996;105-115.
30. Koh J.-Y., Yang L.L., Cotman C.W. β-Amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res. 533:1990;315-320.
31. LaFerla F.M., Tinkle B.T., Bieberich C.J., Haudenschild C.C., Jay G. The Alzheimer's Aβ peptide induces neurodegeneration and apoptotic cell death in transgenic mice. Nat. Genet. 9:1995;21-30.
32. Li G.L., Farooque M., Lewen A., Lennmyr F., Holtz A., Olsson Y. MAP2 and neurogranin as markers for dendritic lesions in CNS injury. An immunohistochemical study in the rat. Apmis. 108:2000;98-106.
33. Loo D.T., Copani A., Pike C.J., Whittemore E.R., Walencewicz A.J., Cotman C.W. Apoptosis is induced by β-amyloid in cultured central nervous system neurons. Proc. Natl. Acad. Sci. USA. 90:1993;7951-7955.
34. 2+ homeostasis in Alzheimer's disease. Trends Neurosci. 16:1993;409-414.
35. Mattson M.P., Cheng B., Davis D., Bryant K., Liebergburg I., Rydel R.E. β-Amyloid peptides destabilize calcium homeostasis and render human cultured neurons vulnerable to excitotoxicity. J. Neurosci. 12:1992;376-389.
36. McGeer P.L., McGeer E.G., Yasojima K. Alzheimer disease and neuroinflammation. J. Neur. Transm. Suppl. 59:2000;53-57.
37. Meldrum B., Garthwaite J. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol. Sci. 11:1990;379-387.
38. Miguel-Hidalgo J.J., Cacabelos R. β-Amyloid(1-40)-induced neurodegeneration in the rat hippocampal neurons of the CA1 subfield. Acta Neuropathol. 95:1998;455-465.
39. Miller J.D., Cummings J., Maresh G.A., Walker D.G., Castillo G.M., Ngo C., Kimata K., Kinsella M.G., Wight T.N., Snow A.D. Localization of perlecan (or a perlecan-related macromolecule) to isolated microglia in vitro and to microglia/macrophages following infusion of β-amyloid protein into rodent hippocampus. Glia. 21:1997;228-243.
40. Moechars D., Lorent K., De Strooper B., Dewachter I., Van Leuven F. Expression in brain of amyloid precursor protein mutated in the α-secretase site causes disturbed behavior, neuronal degeneration and premature death in transgenic mice. EMBO J. 15:1996;1265-1274.
41. Moechars D., Lorent K., Van Leuven F. Premature death in transgenic mice that overexpress a mutant amyloid precursor protein is preceded by severe neurodegeneration and apoptosis. Neuroscience. 91:1999;819-830.
42. Muller W.E., Mutschler E., Riederer P. Noncompetitive NMDA receptor antagonists with fast open-channel blocking kinetics and strong voltage-dependency as potential therapeutic agents for Alzheimer's dementia. Pharmacopsychiatry. 28:1995;113-124.
43. Osborne N.N., Herrera A.J. The effect of experimental ischaemia and excitatory amino acid agonists on the GABA and serotonin immunoreactivities in the rabbit retina. Neuroscience. 59:1994;1071-1081.
44. Parsons C.G., Danysz W., Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology. 38:1999;735-767.
45. Parsons C.G., Gruner J., Rozental J., Millar J., Lodge D. Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacology. 32:1993;1337-1350.
46. Penney J.B., Maragos W.F., Greenamyre J.T., Debowey D.L., Hollingsworth Z., Young A.B. Excitatory amino acid binding sites in the hippocampal region of Alzheimer's disease and other dementias. J. Neurol. Neurosurg. Psychiatry. 53:1990;314-320.
47. Reisberg B. Memantine in moderately severe to severe Alzheimer's disease (AD): results of a placebo-controlled 6-month trial. Neurobiol. Ageing. 21:2000;S275.
48. Robinson M.B., Djali S., Buchhalter J.R. Inhibition of glutamate uptake with L-trans-pyrrolidine-2,4-dicarboxylate potentiates glutamate toxicity in primary hippocampal cultures. J. Neurochem. 61:1993;2099-2103.
49. Rothstein J.D., Jin L., Dykes-Hoberg M., Kuncl R.W. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc. Natl. Acad. Sci. USA. 90:1993;6591-6595.
50. Scorziello A., Meucci O., Florio T., Fattore M., Forloni G., Salmona M., Schettini G. β-Amyloid 25-35 alters calcium homeostasis and induces neurotoxicity in cerebellar granule cells. J. Neurochem. 66:1996;1995-2003.
51. Sloane J.A., Hollander W., Rosene D.L., Moss M.B., Kemper T., Abraham C.R. Astrocytic hypertrophy and altered GFAP degradation with age in subcortical white matter of the rhesus monkey. Brain Res. 862:2000;1-10.
52. Stieg P.E., Sathi S., Warach S., Le D.A., Lipton S.A. Neuroprotection by the NMDA receptor-associated open-channel blocker memantine in a photothrombotic model of cerebral focal ischemia in neonatal rat. Eur. J. Pharmacol. 375:1999;115-120.
53. Taft W.C., Yang K., Dixon C.E., Hayes R.L. Microtubule-associated protein 2 levels decrease in the hippocampus following traumatic brain injury. J. Neurotrauma. 9:1992;281-289.
54. Vijayan V.K., Lee Y.L., Eng L.F. Increase in glial fibrillary acidic protein following neural trauma. Mol. Chem. Neuropathol. 13:1991;107-118.
55. Walker L.C., Price D.L., Voytko M.L., Schenk D.B. Labeling of cerebral amyloid in vivo with a monoclonal antibody. J. Neuropathol. Exp. Neurol. 53:1994;377-383.
56. Watt J.A., Pike C.J., Walencewicz-Wasserman A.J., Cotman C.W. Ultrastructural analysis of β-amyloid-induced apoptosis in cultured hippocampal neurons. Brain Res. 661:1994;147-156.
57. Westerman M.A., Cooper-Blacketer D., Mariash A., Kotilinek L., Kawarabayashi T., Younkin L.H., Carlson G.A., Younkin S.G., Ashe K.H. The relationship between Aβ and memory in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci. 22:2002;1858-1867.
58. Willard L.B., Hauss-Wegrzyniak B., Danysz W., Wenk G.L. The cytotoxicity of chronic neuroinflammation upon basal forebrain cholinergic neurons of rats can be attenuated by glutamatergic antagonism or cyclooxygenase-2 inhibition. Exp. Brain Res. 134:2000;58-65.